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ABSTRACT
SIMULA TION STUDY FOR THE LEAD TIME IN CANCER SCREENING WHEN
HUMAN LIFETIME IS A COMPETING RISK
Sarah K. Kendrick
April 16,2013
PURPOSE: The purpose of this paper is to examine the lead time distribution in
cancer screening trials when lifetime is a random variable in order to determine optimal
initial age at screening and screening frequency. METHODS: Simulation was used in
order to estimate the distribution of the lead time for a hypothetical individual with a
future screening schedule. The lifetime distribution used comes from the Social Security
Administration's actuarial life tables. The lead time distribution was then calculated
based on two different sojourn time distributions (log-logistic and exponential) with four
mean sojourn times (2, 5, 10, and 20 years), using three different initial screening ages,
to=40, 50, 60, and four different screening frequencies, every six months, every year,
every 1.5 years, and every two years for both males and females. RESULTS: Smaller
time intervals between screenings yield a smaller probability of no benefit and a greater
expected lead time.
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INTRODUCTION

Cancer has been sweeping the nation in recent history, and there has been a lot of
research on cancer treatments and effective screening for cancer. Among men, prostate
cancer is the most common cancer followed by lung cancer and colorectal cancer with
lung cancer being the leading cause of cancer death in men followed by prostate cancer.
For women, the most prevalent cancers are breast cancer, followed by lung cancer, and
then colorectal cancer with lung cancer being the leading cause of cancer death, followed
by breast cancer (Centers for Disease Control and Prevention, 2009).
Each type of cancer has a different screening methodes) used for early detection
which could lead to a better prognosis. Prostate cancer has two different screening
methods, a digital rectal exam (DRE) and a prostate specific antigen test (PSA).
However, the United States Preventative Services Task Force does not recommend
getting the PSA test for men who are asymptomatic (U.S. Preventative Services Task
Force, 2012). Screening options for breast cancer consist of self exams, mammograms,
and clinical breast exams. Lumps and changes in size or shape of the breast(s) or
underarm are warning signs for breast cancer, and are usually detected by self or clinical
examination (examination by a nurse or doctor). Even though these two methods can be
helpful in detecting breast cancer, they have not been shown to decrease one's risk of
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death from breast cancer. However, getting regular mammograms, an X-ray of the
breasts, has been shown to decrease an individual's risk of death due to breast cancer
(Centers for Disease Control and Prevention, 2012). Screening options for lung cancer
include chest X-rays, sputum cytology, and CT scans but there is debate over whether
any of these actually help in decreasing deaths from lung cancer (Centers for Disease
Control and Prevention, 2011). Colorectal cancer, liver cancer, and all other cancers have
screening testes) just as the cancers mentioned above. Screening is more beneficial in
some cancers, such as breast cancer, than others, such as lung cancer.
The most common model for the progression of cancer is one occurring in three
stages: So, Sp, and Sc (ZELEN & FEINLEIB, 1969). So is known as the disease-free state,
Sp is the preclinical state in which the individual has developed the disease, and can be
detected by screening, but has shown no clinical symptoms, and Sc is the clinical state in
which the individual exhibits clinical symptoms. The difference in time between the age
at which an individual enters the preclinical state and the age the individual begins to
experience clinical symptoms (tc-tp where tc>tp) is defined as the individual's sojourn
time. If disease was detected by screening after the individual entered the preclinical
state, but prior to experiencing any symptoms, the time difference between the age at
detection by screening and the age at onset of symptoms is referred to as the individual's
lead time.
The topic of lead time has been an area of much research over the past 20 to 30
years. Many studies have worked to determine the parameters, formulas, and distributions
that most accurately estimate the important descriptive statistics for the lead time
distribution, such as mean and variance. One of the largest contributions to the topic of
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lead time was the work done by Prorok in 1982. Prorok's goal was to determine the
optimal number of screenings required for effective and efficient evaluation in repetitive
screening trials. He used the lead time properties of screen detected cases to develop a
stopping rule for these kinds of studies. What he found was that the lead time tended to
stabilize after four to five screenings when the screening frequency was held constant.
This property showed that any screenings in excess of the fourth or fifth one may no
longer provide any additional information. However, Prorok's design contained one
major hole: he did not take interval cases, where lead time is zero, into account (Prorok,
1982). Wu et al. (2007) took the method proposed by Prorok a little further. They
included both screen-detected cases, and interval cases in order to derive the probability
distribution function for the lead time, and used Prorok's results in their model as a
special case - where there are no interval cases. However, Wu et al. (2007) derived the
lead time distribution while assuming that lifetime is a fixed value, which is unrealistic.
Then, in 2012, Wu et al. extended their previous method to the case where lifetime is
subject to competing risks, and is, therefore, a random variable.
In this paper we will extend the research done by Wu, Kafadar, Rosner, and
Broemeling in 2012. We will look at the lead time distribution for several different
screening situations in order to gain an understanding of how/if screening is beneficial for
different cancers. We will look at three hypothetical cohorts of initially asymptomatic
men and women. The three cohorts will be based on initial age at screening: 40, 50, and
60 years old. Within each cohort we will examine the effect of four different screening
frequencies on the lead time distribution: delta = 6 months, one year, one and a half
years. and two years. We will also look at two different distributions for the sojourn time:
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log logistic and exponential. Our results will give insight into the benefits of screening
for different types of cancers, as well as the ideal initial screening age and screening
frequency.
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METHODS

Lead Time Distribution when Lifetime is Fixed
This study used simulation data to determine the lead time distribution for a
hypothetical cohort of initially asymptomatic individuals with no history of cancer. First
we must define some variables and notation. Let t be the age of the individual at a
screening exam, to be the age at which the individual has their initial screening, T be the
individual's lifetime, L indicate the lead time, D be a binary random variable using D=1
to indicate disease development and 1)=0 to indicate no disease, and K be the total
number of screenings the individual will undergo in their lifetime. Now we let f3(t) be the
sensitivity of the screening modality and define w(t)dt as the probability that an
individual will transition from the disease-free state(So) to the preclinical state (Sp) during
the interval (t, t+dt); q(x) as probability distribution function of the sojourn time, and
Q(z) =

Jzoo q(x)dx as the survivor function for the sojourn time. From the Health

Insurance Plan for Greater New York (HIP) study we know that f3(t) was characterized
using a logistic model,
1

(J(t) = - - - - - - 1 + exp {- b o - b1 (t - f)}
Where f=the average age at entry. The transition density function is that of a log normal
(11,

()2)

density function multiplied by 0.2, the upper limit of lifetime risk,
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2
0.2
{(109t - 11)2}
w(tll1, a ) = r-c exp 2 2
'
v 2Trat
a

a > O.

Finally, we will use the log logistic and the exponential distributions to define the sojourn
time distribution. This yields the following survivor and hazard functions:
1. Log logistic

KXK-lpK

1

Q(x)

= 1 + (Xp)K

and

hex)

= 1 + (Xp)K'

K

> 0,

P > 0, and

2. Exponential

Q(x) = e- itx and

hex) = A.

We then combine these two functions to define the density function for the sojourn time:
q(x) = h(x)Q(x), where x is the sojourn time. The above equations contain the following
unknown parameters, b o, b l , /1,

(i, K, and p (Wu, Rosner, &

Broemeling, 2005).

Each individual undergoes a set of K screening exams during their lifetime at the
ages of to<tl <t2<' .. <tK-I. For the sake of simplicity we let T=tK even though there is no
screening at age T. We now look at the distribution oflead time when lifetime is a fixed
value. As we mentioned in the introduction, lead time consists of two parts: a point mass
at zero, peL

= OlD = 1, T = t K ), indicating an interval case, and a continuous

conditional probability distribution function, fL(ziD = 1, T = tK)'
We show that:

peL

= OlD = 1, T = t K ) =

Where
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peL = O,D = liT = t K )
P( _ IT _ )
,
D - 1 - tK

=

f

tK It

~

+

w(x)q(t - x)dxdt

= Ito w(x) [Q(to -

0

x) - Q(t K - x)]dx

0

tK

fto

w(x) [1 - Q(tK - x)] dx

And

+ f tj

W (x)

[ 1 - Q(tj -- x)] dx

tj-l

And where

fL (z, D = liT = t K) = Po
Or

I

0

to

w(x)q(t o + z - x)dx

fL(z,D = liT = t K )
~j-l

ftr

{~i-l
= Li=l Pi Lr=o (1- Pr) ... (1 - Pi-l) t
t.
+ ti~l
w(x)q(t i + z -

f

x)dx

}

w(x)q(ti + z - x)dx

r

1

+ Po l~
0 w(x)q(t o + z -

if tK - tj < z :::;; tK - tj-1,j = 2,3, ... , K
We can prove the validity of this probability by confirming that

(Wu, Rosner, & Broemeling, 2007).
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x)dx

The Lifetime Distribution

In order to find the distribution of lifetime, we used the actuarial table provided
by the Social Security Administration. This life table provides information on the
probability of mortality, the conditional probability of death within one year (P(T <
N+ liT 2: N)), and life expectancy for both men and women, N=O, 1, 2, ... ,119. It is
produced using data from all Social Security populations which is comprised of residents
of the United States and the District of Columbia, civilian residents of U.S. territories,
civilian Federal employees, individuals in the U.S. Armed Forces abroad and their
dependents, and all other U.S. citizens (Social Security Administration, 2012).
To obtain the distribution for the lifetime, some derivations are needed first. If we
let bN = PCT

< N + liT

2: N) and let

aN

= 1 - bN = PCT 2: N

+ liT 2: N), then using

the conditional probability formula we find that,

PCT 2: N + 21T 2: N)
= PCT 2: N

= PCT 2

N + 2, T 2: N + liT 2: N)

+ liT 2: N)PCT 2: N + 21T 2: N + 1, T 2: N)

= aNaN+l

Now we can use mathematical induction to apply this concept to any integer age, to,

n
=n
N

PCT 2: to + NIT 2: to)

=

PCT 2: to + ilT 2: to + i - 1)

i=l

N

a to +i-l

'<IN

= 1,2, ... ,120 -

to·

i=l

Next, we use a density approximation for frCt

= to + NIT

2: to),

fTCt = to + NIT 2: to) = lim PCto + N < T ::;; to + N +
1' ..... 0
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E

IT 2: to)

n
N

=

C1 -

atO+N)

a to +i-l·

i=l

In this case, where N<120, we will use a step function to approximate fTCtIT

;;::: fTCNIT

~

~

to) to be

to) for any real number tin [N, N+ 1]. Finally, we can show the validity of

this probability distribution approximation:
120-to

L

fTCto

+ NIT ~

to)

N=O

120-to

=

L

[PCT

~

to

+ NIT ~ to) -

PCT

~ to + N + liT ~ to)]

N=O

(Wu, Kafadar, Rosner, & Broemeling, 2012).
We now use these results to plot the conditional lifetime distributions for men and
women with initial screening ages of 40, 50, and 60. We must note that this does not take
screening frequency or cause of death into account.
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Figure 1. Conditional lifetime distributions for initial screening ages of 40, 50, and 60.
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Lead Time Distribution When Lifetime is a Random Variable
Using the ideas and formulas when lifetime was a fixed number, we can
determine the distribution of the lead time when lifetime is a random variable by
implementing a few modifications. When lifetime is a random variable, the number of
screenings an individual will receive in their lifetime is also variable and is a function of
their lifetime, K=k(T) where K is the largest integer that satisfies tK-l < T. To obtain the
distribution of the lead time when lifetime is a random variable we define the following,

peL = DID = 1, T ;::: to)

= LXlP(L =

DID

= t, T =

t)fT(tIT ;::: to)dt

to

fL(ziD = 1, T;::: to) =

LXl

fL(ziD = 1, T = t)fT(tIT;::: to)dt

z E (0,00)

to+Z

The lower bound in the above equation is (to+z) instead of to since the lead time should be
less than t-to, therefore, t should be greater than to+z. The equations

peL = DID = t, T = t) and fL(ziD = 1, T = t) come from the situation where lifetime is
a fixed value and the conditional distribution of the lifetime is,

fT(t)
otherwise.

We can show that the equations above are a valid mixed probability distribution:
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peL

= OlD = 1, T :;:::

to) + {"'fL (ziD

= 1, T :;::: to)dz

= lCX) peL = OlD = 1, T = t)fT(tIT :;::: to)dt
to

+ fOO foo fL (ziD = 1, T = t) fT(tiT :;::: to)dtdz
o

1

to+Z

00

=

peL

= OlD = 1, T = t)fT(tIT :;::: to)dt

to

00 rt-to

+

1Jr
to

fL(ziD = 1, T = t) fTCtIT :;::: to)dtdz

0

(Wu et aI., 2012).
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RESULTS

We can apply the above methods to any screening schedule. For our example we
will consider three different initial screening ages for both men and women ofto=40, 50,
and 60. For each initial age we will examine the effects of four different screening
frequencies, L1=0.5, 1.0, 1.5, and 2.0 years. Finally, for each combination of initial
screening age and screening frequency we will consider the case where the sojourn time
has a log-logistic distribution and the case where it has an exponential distribution. The
following tables give the probability of no benefit (lead time equal to zero), for each
initial screening age, screening frequency, and sojourn time distribution combination as
well as the estimate for the probability of benefit, the expected lead time, and the median
lead time (for females only since the results are very similar for males and females).
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Table 1
A projection of the lead time distribution when mean sojourn time = 2 years
Log-Logistic
ph
EL c Med d
I-Po
0
0
Initial Screening Age to=40
28.40
71.60 0.533
2.9
32.26
6 Months
2.7
43.02
44.94
55.06 0.453
12 Months
52.87
47.13 0.380
2.8
51.58
18 Months
63.68
36.32 0.324
2.7
58.59
24 Months
Initial Screening Age to=50
8.34
14.23
91.66 1.42
1.9
6 Months
24.10
75 .90 4.20
24.87
12 Months
1.8
39.97
60.03 1.01
1.8
33.54
18 Months
52.71
47.29 0.861
1.7
40.76
24 Months
Initial Screening Age to=60
5.40
94.6
1.92
1.7
11.32
6 Months
19.56
80.44 1.63
12 Months
1.6
20.80
34.32
65 .68 1.37
1.6
28 .77
18 Months
46.32
53.68 1.18
35.51
24 Months
1.6
a Time between screenings (ti - ti-l)
b Po = P(L=OID= l) = Probability of no early detection (%)
C The mean lead time is in years
d The median when L > 0 (for non-interval cases)
/').3

ph
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Exponential
EL c
I-Po

Med d

67.74
56.98
48.42
41.41

0.745
0.684
0.627
0.578

2.9
2.7
2.8
2.7

85 .77
75.13
66.46
59.24

1.69
1.52
1.55
1.42

1.9
1.8
1.8
1.7

88.68
79.2
71.23
64.49

2.41
2.2 1
2.02
1.86

1.9
1.9
1.9
1.9

Table 2
A projection of the lead time distribution when mean sojourn time = 5 years

8.

Po

6 Months
12 Months
18 Months
24 Months

18.15
20.48
23.06
26.18

6 Months
12 Months
18 Months
24 Months

7.35
20.87
34.43
45.31

6 Months
12 Months
18 Months
24 Months

0.304
1.43
3.42
6.15

Log-Logistic
Exponential
Med
EL
I-Po
I-Po EL Med
Po
Initial Screening Age to=40
23.55
81.85 1.44 4.3
76.45 1.22 4.7
29.40
70.60 1.20 4.5
79.52 1.42 4.1
34.25
76.94 1.38 3.9
65.75 1.18 4.4
73.82 1.35 3.8
38.50
61.5 1.16 4.2
Initial Screening Age to=50
7.47
92.53 2.79 3.0
92.65 3.3 1 3.1
79.13 3.25 2.8
l3.25
86.75 2.73 2.9
18.32
65.57 3.16 2.6
81.68 2.66 2.9
54.69 3.07 2.4
22.91
77.09 2.59 2.8
Initial Screening Age to=60
99.696 4.14 2.7
4.79
95.21 3.60 2.4
9.20
90.8 3.52 2.4
98.57 4.08 2.6
96.58 3.99 2.5
13.29
86.71 3.43 2.4
93.85 3.89 2.4
17.08
82.92 3.36 2.4

Table 3
A projection of the lead time distribution when mean sojourn time = 10 years

8.

Po

6 Months
12 Months
18 Months
24 Months

15.54
16.94
17.84
18.95

6 Months
12 Months
18 Months
24 Months

2.52
3.80
5.29
6.89

6 Months
12 Months
18 Months
24 Months

0.066
0.315
0.779
1.47

Log-Logistic
Exponential
EL Med
I-Po
I-Po EL Med
Po
Initial Screening Age to=40
84.46 1.76 5.9
19.29
80.71 1.25 6.3
83.06 1.81 5.6
23.21
76.79 1.28 6.1
82.16 1.85 5.4
26.40
73.60 1.29 6.0
81.05 1.89 5.2
29.22
70.78 1.31 5.9
Initial Screening Age to=50
97.48 3.70 4.2
5.04
94.96 2.75 3.7
96.2
3.78 4.0
8.87
91.l3 2.76 3.6
94.71 3.83 3.8
12.27
87.73 2.76 3.5
93.11 3.88 3.6
15.40
84.6 2.77 3.5
Initial Screening Age to=60
99.934 4.75 3.6
97.42 3.76 2.9
2.58
99.685 4.81 3.4
5.04
94.96 3.75 2.9
99.221 4.85 .J . .J
7.39
92.61 3.72 2.9
98.53 4.90 3.2
9.64
90.36 3.71 2.8
")

15

")

Table 4
A projection of the lead time distribution when mean sojourn time = 20 years

fj,

Po

6 Months
12 Months
18 Months
24 Months

12.53
13.73
14.47
15.05

6 Months
12 Months
18 Months
24 Months

1.87
3.05
4.07
5.05

6 Months
12 Months
18 Months
24 Months

0.017
0.078
0.193
0.3 66

Log-Logistic
Exponential
EL Med
I-Po
I-Po EL Med
Po
Initial Screening Age to=40
16.44
87.47 4.32 8.1
83.56 1.14 7.1
86.27 4.53 7.7
19.37
80.63 1.18 6.9
21.70
85.53 4.71 7.4
78.30 1.21 6.7
84.95 4.9 1 7.1
23.74
76.26 1.26 6.5
Initial Screening Age to=50
98.13 6.86 5.9
3.81
96.19 2.42 4.4
96.95 7.11 5.6
6.63
93.37 2.47 4.2
95.93 7.31 5.3
9.12
90.88 2.50 4.1
94.95 7.52 5.1
11.43
88.57 2.54 4.1
Initial Screening Age to=60
99.983 8.60 4.3
1.47
98.53 3.55 3.3
99.922 8.72 4.3
3.09
96.91 3.56 3.3
99.807 7.80 4.2
4.57
95.43 3.57 3.3
99.634 8.93 4.1
6.01
93.99 3.58 3.3

The following figures give the density curves for the lead time for the different
screening intervals, sojourn times, and sojourn distributions but only for females when to
=

50 since we get similar results for men and the other initial screening ages.
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Figure 2. Lead time probability distributions when sojourn time distribution is loglogistic
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Exp Lead Time Distribution
for Women when MST=2
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Figure 3. Lead time probability distributions when sojourn time distribution is
exponential
These results show that for a mean sojourn time (MST) of two years and a loglogistic sojourn time distribution, an individual that begins screening at age 40 and
receives screenings twice a year has a 28.4% chance that their cancer will not be detected
by early screening. This value increases to 44.94% and 63.68% when screening
frequency is decreased to once a year and twice a year, respectively. We see a similar
trend for initial screening ages of 50 years, 8.34%, 24. 10%, and 52.71 %, and 60 years,
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5.40%, 19.56%, and 46.32%, for

~

= 0.5, 1.0, and 2.0 years respectively. We find that the

probability an individual will not experience detection by screening increases as
screening frequency decreases when we hold MST and age constant. This probability
decreases as age increases when holding screening frequency and MST constant, and
decreases as MST increases with age and screening frequency held constant.
From the graphs of the lead time distributions based on the log-logistic sojourn
time distribution, we see that the mode, mean, and median are monotonically increasing
as MST increases. We find the same trend for the mean and median when the sojourn
time distribution is exponential, however, the mode when the sojourn time distribution is
exponential is relatively constant across mean sojourn times (right around one year). We
also find that when the MST is two or five years the mean decreases as screening
frequency decreases, but find the opposite effect when the MST is ten or twenty years.
Also, mean increases as age increases with MST and screening frequency being held
constant. The trends we see in the median are that it increases as age increases (frequency
and MST held constant) and decreases as frequency decreases (MST and age held
constant).
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DISCUSSION

We took the model presented by Wu, Kafadar, Roner, and Broemling, 2012 and
derived the lead time distribution for different sets of periodic cancer screening when
lifetime was subjected to competing causes (it was a random variable). This model
extends Wu et al.' s previous work to include more simulations that can apply to cancers
other than breast cancer.
We examined the lead time distribution for two different sojourn time
distributions: log-logistic and exponential, four different mean sojourn times: 2 years, 5
years, 10 years, and 20 years, and four different screening frequencies: twice a year, once
a year, once every year and a half, and every two years, for both men and women. We
found that the outcomes were very similar for both men and women, and therefore it
wasn't necessary to present the results for both genders.
Gathering data from all of these simulations allows us to extend our results to
several prevalent cancers such as breast cancer, prostate cancer, lung cancer, and
colorectal cancer which are some of the most common cancers amongst men and/or
women today. One study examined HIP study population, a sample from Edinburgh, and
a sample from Canada in order to determine the mean sojourn times for each group. They
assumed an exponentially distributed sojourn time and found the mean sojourn times to
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be 2.5, 4.3, and 1.9 (ages 40-49) and 3.1 (ages 50-59), respectively (Shen &
Zelen). Lung cancer and colorectal cancer were found to have similar mean sojourn times
as breast cancer when assuming an exponentially distributed sojourn time. Lung cancer
showed mean sojourn times between 1.38 and 3.86 years (Chien & Chen); proximal
colorectal cancer gave mean sojourn times of 3.86 years for individuals aged 45 to 54
years, 3.78 for 55 to 64 year olds, and 2.70 for 65-74 year olds; and distal colorectal
cancer was found to have mean sojourn times of 3.35 for individuals aged 45 to 54 years,
2.24 for 55 to 64 year olds, and 2.10 for 65 to 74 year olds (Zheng & Rutter). A doctor
could use our results where MST is two or five years and the sojourn time distribution is
exponential to develop an efficient screening program for individuals aged 40 to 60 years
old who are at risk for breast cancer, lung cancer, or colorectal cancer. Another study,
assuming an exponentially distributed sojourn time as well, found the mean sojourn time
for prostate cancer to be 11.3 years for men aged 50 to 59 years and 12.6 years for men
aged 60 to 69 years (Pashayan et al.). In this case, our results where MST is equal to
either 10 or 20 years and the sojourn time distribution is exponential, could be used to
come up with effective screening programs for males at risk for prostate cancer.
The Greater New York Health Insurance Plan study was conducted over 50 years
ago. Therefore, since our estimates for the transition probability distribution, sojourn time
distribution, and sensitivity distribution were adopted from the HIP study, our results may
not be an accurate reflection of current conditions. Also, our simulations only take age
and gender into account as a covariate. In the future, we hope to not only get more
accurate estimates for the aforementioned parameters and distributions, but also to
include some other possible covariates to make our results applicable to more subgroups.
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Finally, our model assumes that sensitivity and sojourn time are independent of each
other even though there is evidence that suggests this may not be the case. In future work,
we may want to examine this relationship more closely.
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